Eltoprazine blueprint is ready to launch! The 8k information is likely the catalyst to the buying pressure since last Friday. Eltoprazine's launch of the Phase IIb study, and patient enrolment may be the spark that is going to ignite the upward move that nearly everyone believes is coming. Have a good look at that link:
http://ir.amarantus.com/all-sec-filings/conte...013699.pdf
Gerald and the BOD and BOA are all over this. No one knows exactly what is needed in terms of financing better than they do. Sit back, buckle your seat belt, and watch this unfold in the coming weeks. 2015 looks to be the epiphany for Amarantus Bioscience!